On January 26, 2022 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, reported that the Company will be presenting at the B. Riley Securities Oncology Conference being held virtually on January 27-28, 2022 (Press release, Synthetic Biologics, JAN 26, 2022, View Source [SID1234607411]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Synthetic Biologics, Inc. www.syntheticbiologics.com (PRNewsFoto/Synthetic Biologics, Inc.)
Steven Shallcross, Chief Executive Officer and Chief Financial Officer of Synthetic Biologics, Manel Cascalló, PhD, Chief Executive Officer of VCN, and other key members of Company management are scheduled to present on Friday, January 28, 2022 at 2:30 PM Eastern Time. The live presentation will be available at View Source and a replay of the presentation will be publicly available under the "News/Events" section of the Synthetic website at View Source